Sheldon Freeman

Sheldon Freeman

Partner at Goodmans LLP
(416) 597-6256
(416) 979-1234
333 Bay St, Suite 3400, Bay Adelaide Ctr, W Twr, Toronto, ON
Year called to bar: 1997 (ON)
Partner. Leading practice in M&A, corporate finance and securities law. Recognized for his successes in completing sophisticated transactions with efficiency and precision and has a reputation for resolving complex issues in a practical manner. Known for his regular involvement in high-profile transactions and expertise in corporate governance. Sheldon’s strong corporate and securities law practice and significant expertise in completing a wide range of multi-faceted transactions have provided him with numerous opportunities to act on behalf of buyers, sellers, boards, independent committees and for underwriters and issuers in public offerings. Substantial general corporate practice, advising various clients on issues ranging from formation to shareholder disputes and liquidity events. Placed in the top tier of his peers in terms of his exposure to complex, high-profile proxy contests, public take-over bids and other merger and acquisition transactions. Recognized as a leading lawyer by Best Lawyers in Canada for corporate, leveraged buyouts and private equity, M&A, and securities law, The Canadian Legal Lexpert Directory for corporate finance & securities and M&A and the Lexpert Special Edition: Finance and M&A 2022. Past member of the Securities Advisory Committee of the OSC.
Sheldon Freeman is a featured Leading Lawyer in:
Canadian Legal Lexpert Directory
Repeatedly Recommended
Canadian Legal Lexpert Directory
Repeatedly Recommended
Sheldon Freeman is also listed in the following publication(s)
Read more about Sheldon Freeman in ...
On Sept. 2, Brookfield Property Partners L.P. announced the final results of its substantial issuer bid to purchase up to 74,166,670 of its limited partnership units
Sunovion Pharmaceuticals Inc. (“Sunovion”) completed the acquisition of Cynapsus Therapeutics Inc. (“Cynapsus”) by way of plan of arrangement for approximately $841 million. The acquisition is aligned with Sunovion’s global strategy to expand and diversify its portfolio in key therapeutic areas, including neurology.
Mettrum Health Corp. (Mettrum) completed the sale of all of its issued and outstanding shares to Canopy Growth Corporation (Canopy) by plan of arrangement, whereby Mettrum shareholders received 0.7132 common shares of Canopy for each Mettrum common share held, representing consideration of $8.42 per common share and a total transaction value of approximately $430 million, based on the respective closing prices prior to announcement of the transaction.